close

Agreements

Date: 2011-05-04

Type of information: Licensing agreement

Compound: Debio 1036

Company: Debiopharm (Switzerland) Yale University (USA)

Therapeutic area: Autoimmune diseases - Inflammatory diseases

Type agreement:

licensing
development
commercialisation

Action mechanism:

Debio 1036 is an orally available small molecule that antagonizes a key mediator in the inflammation process. This therapeutically important target is unique in several ways due to its action early on in the inflammatory cascade and its ability to regulate cell growth and apoptosis.

Disease:

Details:

* On May 4, 2011, Debiopharm and Yale have announced an exclusive license agreement for the development and commercialization of Debio 1036, a first-in-class inhibitor for autoimmune and inflammatory diseases.The Debio 1036 project aims at developing inhibitors targeting a fundamental inflammatory pathway, which plays essential roles in myriad diseases progression and severity” said Dr Rolland-Yves Mauvernay, president and founder of Debiopharm S.A.

Financial terms:

Latest news:

Is general: Yes